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Keratinocytes of patients with atopic dermatitis pro-
duce high amounts of granulocyte/macrophage
colony-stimulating factor, a factor essential for den-
dritic cell function and thus for the development of
skin immune responses. In contrast to keratinocytes
cultured from nonatopic, healthy individuals,
granulocyte/macrophage colony-stimulating factor
mRNA could be detected in unstimulated cultures of
atopic dermatitis keratinocytes, and phorbol myrist-
ate acetate induced much greater granulocyte/
macrophage colony-stimulating factor mRNA levels
in these cells, although the decay kinetics were not
altered. Using reporter gene (chloramphenicol acetyl
transferase) analysis, a minimal granulocyte/macro-
phage colony-stimulating factor promoter was
shown to confer constitutive and phorbol-myristate-
acetate-induced regulation of transcriptional activity
in keratinocytes, and signi®cantly higher levels of
chloramphenicol acetyl transferase activity were
measured in lysates of unstimulated and phorbol-
myristate-acetate-treated atopic dermatitis keratino-
cytes than in control keratinocyte cultures. Electro-
phoretic mobility shift assays showed that low levels
of NF-kB binding activity could be induced by
phorbol myristate acetate in both normal and atopic
dermatitis keratinocytes. By contrast, activator pro-
tein 1 complexes were ef®ciently induced, and they
were invariably present at higher levels in nuclear
lysates of atopic dermatitis keratinocytes. Atopic der-
matitis keratinocyte nuclear lysates had higher con-
stitutive levels of c-Jun, and phorbol myristate
acetate promoted an earlier and stronger expression
of c-Jun, JunB, and of the phosphorylated forms of
c-Fos. A dysregulated activation of activator protein
1 may be implicated in the molecular mechanisms
leading to increased granulocyte/macrophage
colony-stimulating factor expression in atopic
dermatitis keratinocytes. Key words: cytokines/in¯am-
mation/skin/transcription factors. J Invest Dermatol
115:1134±1143, 2000
A
topic disorders comprise diseases such as atopic
dermatitis (AD), bronchial asthma, and rhinocon-
junctivitis, affecting tissues (i.e., the skin and
mucosae) that de®ne boundaries between the host
and the environment. They are characterized by IgE
hyperresponsiveness to common environmental allergens, and by a
peculiar hyperreactivity of the target tissues towards a variety of
in¯ammatory stimuli (Postma et al, 1995; Nimer et al, 1996). The
preferential development of T helper 2 (Th2) immune responses in
atopic patients has been associated with abnormal regulation of
cytokine genes and signaling pathways (Welter and Eckert, 1995;
Khurana Hershey et al, 1997; Ray and Cohn, 1999). In contrast,
the cellular and molecular bases of the target tissue hyperreactivity
have been only marginally investigated (Pastore et al, 1997;
Sampath et al, 1999). Epithelial cells are the outermost component
of skin and mucous membranes, and they can be activated by
diverse factors to produce cytokines involved in the initiation and
ampli®cation of in¯ammatory and immune responses (Pastore et al,
1997; 1998; Albanesi et al, 1999).
Granulocyte/macrophage colony-stimulating factor (GM-CSF)
is a pleiotropic cytokine exerting multiple effects on dendritic cells,
T cells, monocytes, and eosinophils. In a rat compartmentalized
transgene model, a prolonged skin expression of GM-CSF induced
changes commonly observed in AD (Xing et al, 1997). GM-CSF is
readily produced by epithelial cells in response to autocrine
interleukin-1a (IL-1a) and tumor necrosis factor a (TNF-a), and
to the T-cell-derived cytokines interferon-g (IFN-g), interleukin
(IL)-4, and IL-17 (Pastore et al, 1997; 1998). In the context of
atopic diseases, a prominent increased expression of GM-CSF has
been documented in nasal and bronchial epithelial cells of rhinitis
and asthma patients, respectively (Marini et al, 1992; Sousa et al,
1993; Nonaka et al, 1996; CalderoÂn et al, 1997), as well as in
peripheral blood mononuclear cells of AD patients (Bratton et al,
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1995). We have previously shown that GM-CSF is overexpressed
in keratinocytes of AD lesions, and that keratinocytes cultured from
nonlesional skin of AD patients produce higher levels of GM-CSF,
both basally and in response to IL-1a, IFN-g, or phorbol myristate
acetate (PMA), compared with keratinocytes from nonatopic
individuals. These ®ndings could have important implications in
the differentiation and sustained activation of dendritic cells in AD
skin (Pastore et al, 1997; Xing et al, 1997). GM-CSF expression is
regulated by a combination of transcriptional and post-transcrip-
tional control mechanisms (Gasson, 1991). GM-CSF gene is
constitutively transcribed, although its mRNA cannot be normally
accumulated in the cells, due to instability of this transcript (Malter,
1998). Among stimuli effective in inducing GM-CSF, PMA has
been characterized extensively and demonstrated to both increase
GM-CSF mRNA stability and directly stimulate GM-CSF gene
transcription (Shaw and Kamen, 1986; Malter, 1998). Deletion
analysis of the GM-CSF 5¢ ¯anking region showed that a minimal
promoter fragment spanning from 91 nucleotides (nt) upstream to
23 nt downstream of the mRNA cap site was suf®cient for
directing constitutive and inducible transactivation (Kaushansky,
1989; Kaushansky et al, 1996). Two regulatory elements within this
region, the Conserved Lymphokine Element 2 (CLE2, located
between ±85 and ±76 nt upstream of the cap site) and CLE0 (from
±53 to ±39 nt), contribute to an ef®cient GM-CSF gene
transactivation in an interdependent and synergistic fashion. The
major transcription factors known to be critically responsible for
basal as well as induced gene transactivation are NF-kB and
activator protein 1 (AP-1) binding CLE2 and CLE0, respectively
(Jenkins et al, 1995; Kaushansky et al, 1996; Nimer et al, 1996;
Thomas et al, 1997). In addition, both activating and repressor
elements have been recognized in the region between CLE2 and
CLE0, although their speci®c functions have not been fully
characterized (Shannon et al, 1997).
In this study, keratinocytes cultured from AD patients were
shown to have a higher GM-CSF gene transcriptional activity than
keratinocytes cultured from healthy subjects. In addition, AP-1
complexes were over-represented in AD keratinocytes, with higher
levels of basal c-Jun and PMA-induced c-Jun, JunB, and
phosphorylated forms of c-Fos. Finally, the pattern of AP-1
expression in lesional AD keratinocytes was markedly disturbed.
These results provide initial evidence for an important role of AP-1
transcription factors in the pathophysiology of AD.
MATERIALS AND METHODS
Subjects Seventeen adult patients (nine males and eight females; age
range, 15±39 y; median age, 26 y) with moderate to severe chronic AD,
diagnosed according to standard criteria (Hani®n and Rajka, 1980),
participated in the study. Skin involvement ranged from 20% to 60% of the
body surface area. Ten patients had associated bronchial asthma and/or
rhinoconjunctivitis, whereas seven patients had pure AD. Serum IgE was
elevated in 13 patients (120-2000 kU per ml). Patients were not receiving
any systemic or topical therapy for at least 2 wk and 1 wk before testing,
respectively. The ®rst eight patients had already been included in a previous
study (Pastore et al, 1997). Nine healthy individuals (®ve males and four
females; age range, 20±50 y; median age, 32 y) served as controls. They had
no personal or family history of atopic diseases, and serum IgE levels were
within normal limits. Epidermal sheets for keratinocyte cultures were
obtained from the roof of suction blisters raised on normal-looking skin of
all patients and ®ve control subjects. In four control subjects, skin was
obtained during plastic surgery. Four millimeter punch biopsies were taken
from lesional skin of the elbow of three AD patients and from normal
elbow skin of three nonatopic controls. Informed consent was obtained
from all subjects, and the study was approved by the Istituto Dermopatico
dell'Immacolata Ethical Committee.
Reagents and antibodies PMA was purchased from Sigma-Aldrich
(Milano, Italy). Actinomycin D was from Boehringer Mannheim
(Mannheim, Germany), and poly-(dI-dC) from Pharmacia Biotech
(Uppsala, Sweden). Protein phosphatase 1 (PP1) was from New England
Biolabs (Beverly, MA). Unless otherwise speci®ed, the antibodies were
af®nity-puri®ed rabbit polyclonal IgG. Anti-NF-kB p50 subunit (SA-170),
anti-NF-kB p65 subunit (SA-171), and anti-NF-kB c-Rel (SA-172)
antibodies were from Biomol Research Laboratories (Plymouth Meeting,
PA). Anti-inhibitor of kBa (IkBa; sc-371), anti-pan-Jun (sc-44), anti-
c-Jun (sc-45, goat), anti-JunB (sc-46), anti-JunD (sc-74), anti-pan-Fos
(sc-413, mouse monoclonal antibody IgG2a), anti-c-Fos (sc-52), anti-FosB
(sc-48), anti-Fra-1 (sc-605), anti-Fra-2 (sc-171), anti-Ets-1 (sc-112), anti-
YY1 (sc-1703), anti-Sp1 (sc-59), and anti-C/EBPd (sc-636) antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Secondary antibodies employed in Western blot analysis were horseradish
peroxidase conjugated antigoat IgG (sc-2020) or antirabbit IgG (sc-2004),
from Santa Cruz. For immunohistochemistry, biotinylated antirabbit and
antigoat IgG were purchased from Vector Laboratories (Burlingame, CA).
Keratinocyte cultures Primary keratinocyte cultures were established
by seeding epidermal cells on a feeder layer of irradiated 3T3/J2 ®broblasts,
as described previously (Pastore et al, 1997). Second-or third-passage
keratinocytes were used in all experiments, with cells cultured in the
serum-free medium Keratinocyte Growth Medium (KGM; Clonetics, San
Diego, CA), prepared from the essential nutrient solution Keratinocyte
Basal Medium (KBM; Clonetics), supplemented with optimal
concentrations of epidermal growth factor, hydrocortisone, insulin,
bovine pituitary extract, and antibiotics. GM-CSF release was assessed in
cells from all subjects, whereas the other assays were repeated on
keratinocytes cultured from the same two to four AD patients or control
individuals, as indicated in the ®gure legends.
Enzyme-linked immunosorbent assay (ELISA) Quantitation of
GM-CSF was performed on supernatants collected after 48 h treatment
with 10 ng per ml PMA of triplicate subcon¯uent keratinocyte cultures
using the GM-CSF Predicta kit from Genzyme (Cambridge, MA). During
the assay, keratinocytes were grown in medium devoid of hydrocortisone.
RNA isolation, RNAse protection assay (RPA) and semiquantit-
ative reverse transcriptase polymerase chain reaction (RT-PCR)
analysis Total RNA was extracted with a modi®ed guanidine
isothiocyanate acid phenol protocol using Ultraspec RNA Isolation
System (Biotecx, Houston, TX), as described previously (Pastore et al,
1997). For RPA, the multiprobe template set hCK4 and the complete kit
for this assay were purchased from PharMingen (San Diego, CA), and were
used according to the manufacturer's instructions. Ten micrograms of
RNA was used in each assay. RPA bands were quanti®ed by laser
densitometry using an imaging densitometer supported by the Molecular
Analyst image analysis software (Bio-Rad, Hercules, CA), with GM-CSF
mRNA signals normalized to those of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). For RT-PCR analysis, 1 mg RNA was reverse
transcribed and the cDNA was ampli®ed using the GeneAmp RNA PCR
kit (Perkin-Elmer, Roche Molecular Systems, Branchburg, NJ). The
primers for c-Fos ampli®cation were taken from Lane et al (1998), and
those for the other AP-1 subunits were from Risse-Hackl et al (1998). A
GAPDH primer set was used as an internal control for the amount of RNA
used. The optimal number of ampli®cation cycles for each primer set was
deduced from the exponential tract of the line obtained from a
semilogarithmic graph in which cycle numbers were plotted against the
optical densities of the corresponding PCR band.
Plasmid constructs and keratinocyte transfection The chlor-
amphenicol acetyl transferase (CAT) reporter construct carrying the
sequence of the minimal GM-CSF promoter, from 91 nt upstream to 23
nt downstream of the GM-CSF cap site (p91 CAT), has been previously
described (Kaushansky, 1989). Site-speci®c mutations in the native
sequence of p91 CAT were introduced to identify its functional elements
(Kaushansky et al, 1996). Keratinocytes were transfected with plasmids
carrying random mutations of ®ve nucleotides within the GM-kB
sequence, localized in the CLE2 site (p91 m CAT), two different random
trinucleotide substitutions in the CLE0 element, known to bind AP-1
proteins (p91 m6 CAT and p91 Oct+ CAT), a seven nucleotide mutation in
the region between CLE2 and CLE0 (p91 m3 CAT), and ®nally
simultaneous mutations at GM-kB and AP-1 sites (p91 mOct+ CAT)
(Fig 3A). The empty expression vector pCAT was used in some
experiments as a negative control. Keratinocytes were seeded onto
1.9 cm2 wells (2 3 105 cells per well), and transfected when
approximately 60% con¯uent, following an established methodology
(E®mova et al, 1998), with some modi®cations. Transfection of
keratinocytes was performed over a 6 h period in 1 ml KGM containing
12 ml lipofectin (Life Technologies, Gaithersburg, MD), 1 mg CAT test
plasmid, and 1 mg pCMV´SPORT-b-galactosidase (b-gal) (Life
Technologies), the last used to provide an internal parameter of
transfection ef®ciency (Awane et al, 1999). After 6 h, transfection
medium was removed, and keratinocytes were allowed to recover in
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fresh KGM for 24 h and then cultured for 12 h with KGM in the absence or
presence of 10 ng per ml PMA. Cultures were then washed with
phosphate-buffered saline and treated with 0.5 ml of lysis reagent
(Boehringer Mannheim), and protein concentration was determined
according to the method of Bradford (Bio-Rad). CAT and b-gal were
measured in aliquots of each lysate as enzyme concentrations (ng per ml)
using commercially available ELISA kits (Boehringer Mannheim). CAT
activity was expressed as CAT concentration normalized to b-gal
concentration 3 500, per microgram of protein. All assays were
performed in triplicate.
Preparation of cytoplasmic and nuclear extracts Keratinocytes were
grown in 75 cm2 ¯asks to 70%±80% con¯uence, and, to reduce background
activation and synchronize the cells, culture medium was replaced with
KBM supplemented with 0.1% bovine serum albumin for 24 h before
stimulation with 50 ng per ml PMA. Keratinocytes and Jurkat cells were
lyzed according to Schreiber's method (Schreiber et al, 1989). To evaluate
the contribution of phosphorylation to the expression of speci®c
transcription factors, aliquots of 10 mg of nuclear lysates were incubated
with 1 unit of PP1 per reaction mixture for 1 h at 30°C, in a reaction buffer
supplemented with 1 mM MnCl2. Lactate dehydrogenase activity (LDH)
was assayed to estimate possible contamination of nuclear extracts with
cytoplasmic proteins (Arenzana-Seisdedos et al, 1995). Protein samples
were diluted to allow determination of initial rates, and values were
expressed as variation of optical density at 340 nm per min per mg of
protein (DOD/min mg).
Electrophoretic mobility shift assay (EMSA) EMSA was performed
as described (McDonald et al, 1997), with some modi®cations. In particular,
binding reactions were performed using 10 mg nuclear proteins per assay in
25 ml binding buffer (25 mM HEPES pH 7.9, 0.5 mm ethylenediamine
tetraacetic acid, 0.5 mM dithiothreitol, 1% Nonidet P-40, 5% glycerol),
supplemented with 100 mM NaCl and 2.5 mg poly-(dI-dC) to detect
speci®c NF-kB complexes. For detection of speci®c AP-1 complexes,
binding buffer was added containing 80 mM NaCl and 5 mg poly-(dI-dC).
To ascertain the identity of the complexes, 2 mg of a speci®c antibody, or a
combination of antibodies, was added to the reaction mixture (20 min,
37°C). Finally, 50,000 cpm of the 32P-end-labeled double stranded
oligonucleotide was added to the binding mixtures, which were
incubated for a further 30 min at 37°C. The sequence of the synthetic
oligonucleotide (Life Technologies) used as a probe for NF-kB in EMSA
was identical to the sequence ±91 to ±76 nt of the minimal GM-CSF
promoter, added to a repeat of the GM-kB site (underlined): 5¢-
AGTTCAGGTAGTTCCCGCTGGGTAGTTCCC. AP-1 binding
activity was detected taking advantage of a probe homologous to the
fragment ±63 to ±35 downstream of the GM-CSF promoter (AP-1 site
underlined): 5¢-CATTTTGTGGTCACCATTAATCATTTCCT. In
some experiments, we used probes in which the sequence of speci®c
GM-kB and AP-1 binding sites was mutated as in constructs p91 m CAT
and p91 Oct+, respectively (Fig 3A). For cold competition, a 100-fold
excess of the double stranded oligonucleotide or mutated oligonucleotide
was added to the binding reaction. The resulting samples were
electrophoresed on 6% native polyacrylamide gels in 1% TBE.
Quantitative analysis of the complexes was performed by laser
densitometry.
Westernblot analysis Aliquots of the nuclear or cytoplasmic extracts were
subjected to sodiumdodecyl sulfate (SDS) polyacrylamide gel electrophoresis,
and then transferred overnight onto a nitrocellulose membrane (Amersham)
at 20 V constant with a Bio-Rad transblot apparatus. Transfer ef®ciency was
visualized by reversible Ponceau Red staining. After exposure to the primary
antibody (60 min, 37°C), the membranes were washed and ®nally incubated
for 40 min with horseradish peroxidase conjugated antigoat IgG or antirabbit
IgG. The signal was revealed with enhanced chemiluminescence reagents
(Amersham), as per the manufacturer's protocol. As a positive migration
control for NF-kB/Rel subunits, nuclear extracts from Jurkat T cells were
usually included on the gels.
Immunohistochemistry Skin biopsies were ®xed in 10% buffered
formalin and embedded in paraf®n. Three to four micron tissue sections
were deparaf®nized and then rehydrated. Antigen unmasking was performed
by two consecutive 5 min exposures to microwaves (600 W), each time in
fresh 10 mM citrate buffer (pH 6.0). Sections were treated with 3% hydrogen
peroxide,washed, and then incubated in10%rabbit or goat serum. Incubation
with primary antibody was performed for 1 h at room temperature. Sections
were then stained according to an avidin-biotin-peroxidase technique
(Vector Laboratories), using 3-amino-9-ethyl carbazole as substrate.
Statistical analysis The Mann±Whitney rank sum test was used to
compare GM-CSF release or CAT activity from keratinocyte cultures of
atopic and nonatopic subjects. Wilcoxon's signed rank test was applied for
within-group comparisons before and after PMA stimulation. Data were
expressed as mean 6 SD; p values of 0.05 or less were considered
statistically signi®cant.
RESULTS
Keratinocytes cultured from AD patients show enhanced
GM-CSF release and gene expression compared to keratino-
cytes from nonatopic controls Extending our previous
observations (Pastore et al, 1997, 1998) to a larger group of
patients, we con®rmed that keratinocytes cultured from the
majority of AD patients released exaggerated amounts of GM-
CSF compared with keratinocytes from nonatopic donors, both in
unstimulated cultures and after 48 h treatment with 10 ng per ml
PMA (Fig 1). Next, we followed GM-CSF mRNA induction in
keratinocytes from basal levels to 6 h stimulation with 10 ng per ml
PMA, and its subsequent decay following PMA withdrawal
(Fig 2A). In contrast to unstimulated control keratinocytes,
which had an undetectable GM-CSF mRNA signal, AD
keratinocytes with higher constitutive GM-CSF release
reproducibly displayed a GM-CSF mRNA band. Moreover,
PMA induced a time-dependent increase in GM-CSF mRNA
that was much more pronounced in AD keratinocytes than in
control cultures. Of note, M-CSF mRNA followed an expression
pattern distinct from that of GM-CSF mRNA, and a limited
induction following PMA stimulation. After 6 h of PMA treatment,
the medium was removed and substituted with fresh medium
containing 5 mg per ml actinomycin D, a potent RNA polymerase
II inhibitor. Rapid GM-CSF mRNA decay was observed after an
initial 15 min interval in which mRNA still accumulated. A
calculated half-life of 24 min in keratinocytes from both nonatopic
and AD subjects indicated that GM-CSF mRNA overexpression in
AD keratinocytes was not due to reduced mRNA degradation
(Fig 2B).
Figure 1. Keratinocytes cultured from AD patients release higher
amounts of GM-CSF. Keratinocyte cultures were established from
normal appearing skin of 17 AD patients (s) and from nine healthy,
nonatopic individuals (h). GM-CSF was measured by ELISA on
supernatants collected after 48 h stimulation of subcon¯uent cultures with
medium alone or 10 ng per ml PMA. Both spontaneous and PMA-induced
GM-CSF release from AD keratinocytes were signi®cantly higher
(p = 0.045 and p = 0.02, respectively) than from control keratinocytes.
Each point represents the mean of triplicate cultures.
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The minimal GM-CSF promoter drives basal and PMA-
induced CAT expression in keratinocytes, with higher levels
in AD keratinocytes To evaluate the existence of a possible
difference in GM-CSF gene transcription ef®ciency, keratinocytes
from AD patients and controls were transiently transfected with a
plasmid (p91 CAT) carrying the native sequence of the minimal
GM-CSF promoter, known to direct basal and inducible
transcription of the reporter gene CAT. A series of plasmids
containing site-speci®c mutations was also employed, as reported in
Fig 3(A) (Kaushansky et al, 1996). In all experiments, pCMV´
SPORT-b-gal was cotransfected to control for transfection
ef®ciency, and CAT activity was calculated by normalization of
raw CAT values to the corresponding b-gal values. As shown in
Fig 3(B), the minimal GM-CSF promoter (p91 CAT) conferred
low level constitutive transcriptional activity in unstimulated
keratinocytes, which was signi®cantly higher in AD keratinocytes
than in control keratinocytes. Any mutation in the native sequence
of p91 CAT reduced basal transcriptional activity to undetectable
levels, in both AD and control keratinocytes (Fig 3B). Following
PMA stimulation, p91 CAT activity increased 10±15-fold, and
again AD keratinocytes exhibited much higher levels than control
cells (Fig 3C). Transfection with plasmids carrying site-speci®c
mutations in either the GM-kB box (p91 m CAT) or the CLE0
sequence (p91 m6 and p91 Oct+) produced more than 90%
reduction of PMA-induced CAT activity, whereas mutation of
both sites led to complete loss of activity. Moreover, the
introduction of a seven nucleotide mutation in the region
between the CLE2 and CLE0 regions, as in p91 m3 CAT,
resulted in about a 60% decrease in CAT activity, suggesting that
this mutation interfered with speci®c binding of an activating
transcription factor. An Sp1 binding site has been identi®ed
adjacent to the GM-kB box, both in murine and human GM-CSF
promoters (between ±75 and ±70 nt in the human sequence)
(Shannon et al, 1997). Experimental evidence has been provided
that mutations in this site potently reduce murine GM-CSF
promoter activity (Masuda et al, 1994), and it has been suggested
that it could have an analogous relevance in the human GM-CSF
promoter (Shannon et al, 1997). On the other hand, these site-
speci®c mutations abrogated any difference in transcriptional
ef®ciency between AD and nonatopic keratinocytes, indicating
that the structural integrity of the minimal GM-CSF promoter was
a necessary requisite for functional interdependence and synergism
among the transcription factors. They did not help to identify,
however, which element of the minimal GM-CSF promoter was
responsible for the difference between AD and control
keratinocytes in the levels of transcriptional activity.
In subsequent experiments NF-kB and AP-1 complexes were
investigated in keratinocyte nuclear lysates. Contamination from
cytoplasmic proteins was excluded by LDH assay, with keratino-
cyte or Jurkat cell cytoplasmic lysates giving LDH values of 30±40
DOD/min mg, and nuclear extracts 0.005±0.01 DOD/min mg.
NF-kB complexes from keratinocyte nuclear lysates bind
the GM-kB region only very weakly EMSA (Fig 4A) showed
that GM-kB binding activity in unstimulated Jurkat nuclear lysates
was not detectable, but it was potently induced by PMA (lanes 1±
5). By contrast, PMA induced a poor increase in binding activity
both in nonatopic (lanes 6±10) and AD (lanes 11±15) keratinocyte
nuclear lysates, although in the latter a slightly earlier induction was
consistently observed (lanes 12 and 13 vs lanes 7 and 8). The
speci®city of the slower-migrating GM-kB DNA binding activity
was determined by addition of speci®c antibodies against NF-kB
subunits to the binding reaction, prior to its incubation with the
labeled probe. Figure 4(B) shows that anti-p50 antibody abrogated
the complex and anti-p65 antibody strongly impaired its formation.
On the other hand, anti-c-Rel, anti-Sp1, or control IgG did not
signi®cantly affect the band produced by keratinocyte nuclear
lysates, although anti-c-Rel antibody impaired complex formation
by Jurkat nuclear lysates (not shown). Moreover, the speci®c
complex was completely competed by a 100-fold excess of
unlabeled GM-kB probe, but not of unlabeled oligonucleotide
with mutated GM-kB sites (lanes 9 and 10, Fig 4B). Western blot
experiments (Fig 4C) showed very low levels of p50 and p65
proteins in unstimulated Jurkat cells and keratinocytes, with PMA
inducing both p50 and p65, much more strongly in Jurkat cells than
in keratinocytes. Noteworthy, a slightly earlier induction of p50
and p65 was invariably noticed in AD than in control keratinocytes
(lanes 10 and 11 vs lanes 5 and 6). Figure 4(C) also shows a modest
PMA-induced decrease in the level of cytoplasmic IkBa, more
evident in Jurkat cells than in keratinocytes, where this inhibitor
was present at higher levels. We could not detect IkBa in nuclear
lysates, either from keratinocytes or Jurkat cells.
AP-1 complexes are stronger in AD keratinocyte nuclear
lysates Nuclear lysates from Jurkat cells and keratinocytes were
allowed to form complexes on a labeled duplex oligonucleotide
based on the sequence from ±63 to ±35 bp of the native GM-CSF
promoter, which includes CLE0. The resulting binding activity
was detectable in quiescent keratinocytes, and was promptly
Figure 2. Keratinocytes cultured from AD patients show higher
constitutive and PMA-induced GM-CSF mRNA expression, but
mRNA decay kinetics are similar to control keratinocytes. (A) Total
RNA from AD and control keratinocytes stimulated with 10 ng per ml
PMA for different time-points was subjected to RPA using a multiprobe
template set. After 360 min, cells were washed and then cultured in fresh
medium containing 5 mg per ml actinomycin D (ActD). (B) RPA bands
were quanti®ed by laser densitometry, and GM-CSF mRNA signals
normalized to GAPDH mRNA signals were plotted against time. The
dashed lines represent the time required for 50% of the GM-CSF mRNA
signal present at 360 min of PMA stimulation to decay, in keratinocytes
from AD patients (s) and from normal controls (h). Similar results were
con®rmed in keratinocyte cultures from three AD patients and three
controls.
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upregulated by PMA, with the complex more represented in
nuclear lysates from AD keratinocytes with high GM-CSF
production (Fig 5A). Compared with control keratinocytes, the
complex was three to four times more intense in the nuclei of these
AD keratinocytes in resting conditions, and it was two to three
times stronger at each time-point after PMA stimulation. On the
other hand, nuclear lysates of AD keratinocytes that released lower
amounts of GM-CSF showed a binding activity similar to controls
(data not shown). Moreover, the speci®c complex was completely
abrogated when competed by a 100-fold excess of unlabeled
oligonucleotide, but not of unlabeled probe carrying a random
mutation in the AP-1 binding sequence (lanes 16 and 17, Fig 5A).
Addition of anti-pan-Jun antibody to the reaction mixture
completely abrogated the complex generated by unstimulated
keratinocytes, indicating that it was a speci®c AP-1 signal (Fig 5B).
Binding competition experiments performed by addition of single
antibodies speci®c for each Jun and Fos family member indicated
that basal AP-1 complex in normal and AD keratinocytes was
composed of JunB and Fra-2, with a small contribution of c-Jun
(Fig 5B), whereas anti-Ets1 or anti-YY1 speci®c antibodies did not
alter the constitutive EMSA signal signi®cantly (data not shown).
The complex formed by nuclear lysates from PMA-stimulated
keratinocytes was completely abrogated by anti-pan-Jun plus anti-
pan-Fos antibodies, with competition to AP-1 binding more
ef®ciently accomplished by anti-pan-Jun than by anti-pan-Fos
antibody (Fig 5C). In stimulated keratinocytes, c-Jun and Fra-1
were the major components, even though JunB, c-Fos, Fra-2, and
to a lesser degree JunD, seemed to participate in complex formation
(Fig 5D). The pattern of EMSA complex formation observed in
Fig 5(B)-(D) was similar in nonatopic and AD keratinocytes, and
did not change signi®cantly at the different time-points after PMA
treatment (data not shown).
AD keratinocyte nuclear lysates express higher basal levels
of c-Jun, and PMA induces in these cells an earlier and
stronger expression of JunB and phosphorylated forms of
c-Fos To gain insights into the difference in AP-1 binding
activity between AD and nonatopic keratinocytes, we performed
Western blot analysis using antibodies speci®c for each member of
the AP-1 family. Except for c-Fos, all AP-1 members were
detectable in nuclear extracts from cultured keratinocytes after 24 h
starvation in KBM (Fig 6). Anti-c-Jun antibody detected a doublet,
consisting of a 40 kDa band visibly modulated by PMA and a
nonspeci®c 43 kDa band. Compared to control cells, AD
keratinocytes exhibited signi®cantly higher levels of c-Jun at
baseline, as well as after PMA stimulation. The highest and the
lowest bands of JunB were present in very low amounts in resting
cells, and after PMA treatment three discrete bands progressively
appeared that were induced at higher levels in AD keratinocytes as
soon as 40 min after stimulation (lane 9 vs lane 3). In contrast, the
levels of JunD speci®c bands were not affected by PMA, and were
equally expressed in nonatopic and AD keratinocytes. With regard
to Fos proteins, c-Fos became detectable 20 min after PMA
stimulation, followed by the progressive formation of a ladder of
distinct heavier bands, with an earlier and stronger induction in AD
keratinocytes (lanes 2±6 vs lanes 8±12). FosB was detectable in
quiescent cells, and was not affected by PMA, both in nonatopic
and AD keratinocytes. Finally, both Fra-1 and Fra-2 bands were
constitutively present in resting keratinocytes, with the ®rst weakly
induced and the second not changed by PMA.
The contribution of phosphorylated forms to Western blot
signals of JunB and c-Fos was appreciable in Western blot analysis
of nuclear lysate aliquots treated with PP1, an enzyme that
speci®cally hydrolyzes the phosphate groups on serine and
threonine (Fetrow et al, 1999). Figure 7 shows that the level of
native, nonphosphorylated JunB protein is 2-fold higher in
keratinocytes from AD patients than in nonatopic controls (lane 6
vs lane 3). By contrast, dephosphorylation of c-Fos gave bands of
similar intensity in both keratinocyte types. These data were
suggestive of a higher rate of synthesis of JunB, and of a more
pronounced phosphorylation of c-Fos.
Semiquantitative RT-PCR analysis indicated that PMA stimu-
lated a transient decrease in steady-state levels of c-Jun mRNA in
keratinocytes of both nonatopic and AD patients (Fig 8). This
decrease was more prominent and prolonged in control cells, where
the c-Jun mRNA level recovered in 20 min, compared with a
10 min interval in AD keratinocytes. Also, c-Jun levels reached a
higher peak intensity (at 40 min) and were still detectable at 6 h in
AD keratinocytes. The JunB mRNA steady-state level was very
similar in nonatopic and AD keratinocytes, but underwent some
induction following PMA, increasing after 20 min in AD
keratinocytes and after 30 min in control cells. Interestingly
enough, PMA promoted a transient increase in c-Fos mRNA that
was signi®cantly weaker in AD than in control keratinocytes.
Figure 3. The minimal GM-CSF promoter
drives basal and PMA-induced CAT activity
in keratinocytes, which is stronger in AD
keratinocytes. Keratinocyte cultures were trans-
fected with the indicated minimal GM-CSF pro-
moter constructs (A) for 6 h, and after a 24 h
recover were cultured for 12 h with or without
10 ng per ml PMA. The cells were then harvested,
and extracts were assayed for CAT activity. (B)
Signi®cantly higher levels of basal CAT activity
were measured in lysates of AD keratinocytes
(black bars) than in those of nonatopic keratino-
cytes (white bars), after transfection of p91 CAT
(p = 0.03). When keratinocytes from either nona-
topic or AD subjects were transfected with con-
structs carrying site-speci®c mutations in the
native sequence of the minimal promoter, CAT
activity decreased to undetectable levels. (C)
Compared with basal levels, p91 CAT drove a
10±15-fold increase in CAT activity following
PMA stimulation, and it was signi®cantly higher
in keratinocytes form AD patients (p = 0.003).
Site-speci®c mutations identi®ed a prominent re-
duction in PMA-induced CAT activity. The va-
lues represent the mean 6 SD of four replicates
for each experimental condition. Similar results
were obtained with keratinocytes from three addi-
tional AD patients and three nonatopic controls.
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Finally, FosB exhibited a similar delayed induction in both
keratinocyte types, whereas Fra-1 and Fra-2 mRNAs did not
change signi®cantly upon PMA treatment.
Expression of AP-1 members is markedly perturbed in AD
lesional skin Erythematous chronic lesional skin of three patients
and normal skin of three nonatopic donors were evaluated for
immunoreactivity to AP-1 members, and speci®city of staining was
checked by its strong reduction after preabsorption of the antibody
to a peptide containing the target epitope (not shown).
Nonimmune rabbit (or goat) IgG gave only minimal nonspeci®c
staining (Fig 9). The staining pattern of normal skin was
Figure 4. Keratinocyte nuclear lysates bind very weakly to a labeled
oligonucleotide probe containing tandem repeats of the GM-kB
region. (A) EMSA was performed using 10 mg of nuclear proteins from
Jurkat cells or keratinocytes, in resting conditions or after stimulation with
50 ng per ml PMA for different time-points. (B) GM-kB binding activity of
keratinocyte nuclear lysates was ef®ciently competed by 2 mg per each
binding reaction of anti-p50 or anti-p65 speci®c antibody, but not by anti-
c-Rel antibody or control IgG. Competition experiments with 100-fold
excess of unlabeled probe abrogated the band, whereas competition with a
mutated probe did not affect complex binding. (C) Western blot analyses of
p50 and p65 induction by PMA were performed on 10 mg aliquots of Jurkat
cell or keratinocyte nuclear extracts, whereas IkBa was detected in 10 mg
aliquots of cytoplasmic lysates. A nonspeci®c band at 43 kDa was
characteristically present in the p50 blot of keratinocyte nuclear extracts.
Identical results were observed in keratinocytes cultured from three AD
patients and three controls.
Figure 5. Basal and PMA-induced AP-1 complexes are stronger in
AD keratinocyte nuclear lysates. EMSA was performed using 10 mg of
nuclear proteins from Jurkat cells or keratinocytes and a labeled
oligonucleotide with a sequence based on the region spanning from ±63
to ±35 bp of the minimal GM-CSF promoter. (A) The basal complex
formed by unstimulated nuclear extracts of keratinocytes from AD patients
(lane 11) has an intensity about 3-fold higher than that measured in control
keratinocytes (lane 6). After PMA stimulation, complexes were invariably
stronger in keratinocytes from AD patients. Competition experiments with
100-fold excess of unlabeled probe abrogated the band, whereas
competition with a mutated probe did not affect complex binding. (B)
Basal AP-1 binding activity was completely competed by anti-pan-Jun
antibody (lane 3). Among Fos proteins, only Fra-2 (lane 11) had a relevant
role in basal complex formation. (C) Jun and Fos were principal
constituents of complexes formed by PMA-activated keratinocytes. (D)
All Jun and Fos proteins (except FosB) had some part in PMA-induced
AP-1 complex in keratinocyte lysates. The patterns shown in panels (B)-(D)
are representative of both control and AD keratinocytes, and did not
change signi®cantly at different time-points of PMA treatment (data not
shown). Similar results were observed using keratinocytes from four AD
patients and three controls.
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substantially in agreement with previous observations (Welter and
Eckert, 1995). In particular, staining with anti-c-Jun and anti-JunB
antibodies was diffuse to all epidermal layers, with a slightly more
intense staining in the granular layer. JunD and c-Fos showed
diffuse cytoplasmic staining in all epidermal layers associated with
prominent nuclear staining in the basal and spinous layers,
respectively. FosB, Fra-1, and Fra-2 exhibited faint, diffuse
cytoplasmic and/or nuclear positivity in normal skin, with Fra-1
staining sparing the basal layer. AD lesional skin showed a distinct
pattern of AP-1 protein expression that was similar for all the factors
investigated, with a peculiar strengthening of cytoplasmic,
perinuclear staining (Fig 9g, m), prevalently localized in
keratinocytes of the basal and, less prominently, upper spinous
and granular layers. In contrast, cytoplasmic staining of the
intermediate spinous layer cells was reduced, and nuclear staining,
especially for JunD and c-Fos, disappeared. In¯ammatory dermal
cells showed a strong cytoplasmic positivity for AP-1, particularly
for JunB, JunD, FosB, and c-Fos.
DISCUSSION
Perturbation in signal transduction pathways and in the activation
of transcription factors can be implicated in the pathogenesis of
different aspects of atopic diseases. For example, gain-of-function
mutations in the IL-4 receptor have been identi®ed in atopic
patients (Khurana Hershey et al, 1997). The high IL-4 production
and the preferential expansion of Th2 cells have also been
associated with polymorphisms in the IL-4 promoter (Song et al,
1996) or with alterations in nuclear protein interactions with IL-4
promoter elements (Chan et al, 1996; Wierenga et al, 1999). Based
on experiments in a transgenic mouse model, other authors
suggested that an earlier and stronger induction of JunB in
differentiating Th2 but not Th1 cells could be responsible for a
higher AP-1 transcriptional activity, and consequently for a strong
activation of Th2 cytokine gene expression (Li et al, 1999). Higher
levels of AP-1 DNA binding activity, secondary to increased
generation of c-Fos, have been documented in peripheral blood
mononuclear cells of corticosteroid-resistant patients with atopic
asthma, and glucocorticoid receptor sequestration by AP-1 has
been proposed to cause a reduced sensitivity to the anti-
in¯ammatory effects of these drugs (Lane et al, 1998).
Dysregulated signal transduction could also contribute to set a
local condition of abnormal response to cytokine signaling, and
thus may direct tissue targeting of the atopic state. A constitutive,
abnormal activation of STAT-1 associated with an increased
expression of its speci®c target genes has been selectively detected
Figure 6. Western blot analysis of keratinocyte nuclear lysates.
Unstimulated keratinocytes (lanes 1 and 7) contained all AP-1 family
members except c-Fos. Moreover, keratinocytes from AD patients basally
contained higher levels of c-Jun than nonatopic controls. PMA stimulation
induced an earlier and stronger expression of c-Jun and JunB, and also a
more pronounced pattern of c-Fos phosphorylated forms. Western blot
analyses were performed on 10 mg aliquots of nuclear extracts elecrophor-
esed on a 10% SDS-polyacrylamide gel. Similar results were obtained using
keratinocytes from four distinct AD patients and four controls.
Figure 7. Contribution of phosphorylation to JunB and c-Fos
western blot analysis. Dephosphorylation of Ser and Thr residues
indicates that the level of native JunB protein is signi®cantly higher in AD
keratinocytes, whereas no detectable difference is evident in the levels of
nonphosphorylated c-Fos. Ten microgram aliquots of nuclear lysates were
treated with 1 unit per reaction mixture of PP1 for 1 h at 30°C, and then
subjected to Western blot analysis. Similar results were obtained using
keratinocytes from two different AD patients and two control subjects.
Figure 8. Semiquantitative RT-PCR of AP-1 members. Analysis of
speci®c AP-1 mRNAs indicates that PMA induces a more rapid and
pronounced increase of c-Jun and JunB gene expression in keratinocytes of
AD patients, whereas the transient appearance of c-Fos mRNA is reduced.
RT-PCR analysis was performed on 1 mg of total RNA. An optimal
number of ampli®cation cycles was performed to ensure a linear
ampli®cation of each reverse-transcribed product. Similar results were
observed using keratinocytes from three distinct AD patients and three
controls.
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in bronchial epithelial cells of atopic asthmatic patients, predispos-
ing these subjects to excessive IFN-g-mediated airway in¯amma-
tion (Sampath et al, 1999). In the case of AD, altered cytokine
synthesis by skin cells has been proposed to increase expression of
TNF-a, IL-1b, and IL-12 mRNA in the skin of AD patients after
contact with detergents or aeroallergens (Jurghans et al, 1998).
Indeed, keratinocytes cultured from AD patients show enhanced
GM-CSF, IL-1, and TNF-a gene expression (Pastore et al, 1997,
1998). Increased production of cytokines by resident cells can be
very important for initiation and persistence of in¯ammation and
allergic responses in the skin of AD patients.
In this report we propose that an altered control of gene
transcription could be implicated in the mechanisms underlying
abnormal GM-CSF expression by AD keratinocytes. By analysis of
reporter gene expression, we observed that ef®cient transactivation
of the minimal GM-CSF promoter strictly requires cooperation
between functional AP-1 and NF-kB binding elements, con®rm-
ing the existence of a powerful synergism between these two
regions of proximal GM-CSF promoter (Tsuboi et al, 1994; Jenkins
et al, 1995; Kaushansky et al, 1996; Nimer et al, 1996; Thomas et al,
1997). GM-CSF gene expression in keratinocytes was crucially
controlled by a very modest increase in NF-kB concentration, thus
indicating the particular ef®cacy of NF-kB in stimulating gene
transcription (Tanaka, 1996). Of greater interest, we observed
upregulated activation of AP-1 in AD keratinocytes producing
exaggerated quantities of GM-CSF, suggesting that variations in
AP-1 complexes could drive increased transactivation of GM-CSF,
and possibly of other in¯ammatory genes. Western blot experi-
ments demonstrated that nuclear lysates of these AD keratinocytes
expressed higher levels of c-Jun, both basally and after PMA
stimulation, and phosphorylated forms of JunB and c-Fos
accumulated in these cells earlier and to greater levels than in
control cells. In resting keratinocytes, c-Jun, JunB, and Fra-2
participated in the formation of AP-1 complexes, so that the higher
amounts of c-Jun in quiescent AD keratinocytes could explain their
enhanced constitutive AP-1 activity. On the other hand, PMA
induces a phosphorylation-dependent reduction of c-Jun ubiquitin-
dependent degradation and a prominent increase in c-Jun
transcriptional activity, which also leads to increased synthesis of
c-Jun itself (Ip and Davis, 1998). Even though participation of JunB
in the AP-1 complexes that bound the GM-CSF promoter was
relatively modest, higher nuclear concentrations of this transcrip-
tion factor and its phosphorylated forms could enhance AP-1
activity in AD keratinocytes. JunB exhibits a decreased homo-
dimerization property and a 10-fold weaker DNA binding activity
compared to c-Jun, and thus it was initially thought to repress
c-Jun-mediated transactivation by competition (Deng and Karin,
1993). There is now evidence, however, suggesting that JunB can
be a strong transcriptional activator, and that phosphorylation
ef®ciently provides for its maximal functional activity (Li et al,
1999). The wide pattern of c-Fos speci®c signals in our Western
blot experiments indicated the existence of different phosphoryl-
ation forms. In fact, c-Fos has a number of activation sites, and
phosphorylation at speci®c Ser and Thr residues in its C-terminus
Figure 9. Immunohistochemical localization
of AP-1 transcription factors is markedly al-
tered in AD lesional skin. Biopsies were taken
from normal skin of nonatopic donors (a-d and i-
l) and from lesional AD skin (e-h and m-p). Skin
sections were stained with antibodies against the
indicated AP-1 members using an avidin-biotin-
peroxidase technique and 3-amino-9-ethyl carba-
zole as substrate. Results are representative of
staining performed on biopsies from three AD pa-
tients and three healthy controls. Scale bar: 40 mm.
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has been shown to enhance stability and also to increase its
transactivation capacity (Bannister and Kouzarides, 1995; Chen et al,
1996). In addition, higher levels of active c-Fos, and of AP-1
complexes, are reported to determine a postinductional attenuation
of c-Fos expression through a transrepressive feedback mechanism
(Cahill, 1997) that could possibly explain the lower levels of c-Fos
mRNA expression observed in AD keratinocytes. Apart from being
directly responsible for a more pronounced transactivation of AP-1
target genes, higher levels of phosphorylation of Jun and Fos
proteins could also improve functional interaction with coactiva-
tors, ®nally leading to a more ef®cient stimulation of Jun/Fos
activity, as previously demonstrated (Bannister and Kouzarides,
1995).
In addition to the speci®c alterations in AP-1 activation that we
found in cultures of AD keratinocytes, immunohistochemical
analysis revealed that expression of all AP-1 members was
signi®cantly altered in AD skin, suggesting an important role for
these transcription factors in AD pathophysiology. Quite interest-
ingly, the staining pattern was remarkably similar for all the factors
investigated, with a peculiar increase of cytoplasmic, perinuclear
staining predominantly localized in the keratinocytes of the basal
and, less evident, the upper spinous and granular layers. Moreover,
nuclear staining for JunD and c-Fos was lost. A number of processes
linked to the speci®c function of transcription factors could
interfere with epitope availability, and hence with an accurate
evaluation of transcription factor levels determined by immuno-
histochemistry. In particular, appreciation of nuclear staining could
be altered by conformational changes induced by the degree and
sites of phosphorylation, transcription factor dimerization, or
binding to gene promoters. Furthermore, any speculation on the
meaning of these alterations in AP-1 signals is complicated by the
fact that these factors are involved in the regulation of various
keratinocyte-speci®c genes, including those associated with pro-
liferation and differentiation (Basset-Seguin et al, 1990; Welter and
Eckert, 1995).
The mechanisms that underlie the selective, excessive activation
of c-Jun, JunB, and c-Fos in AD keratinocytes are presently
unknown. It is possible, however, that abnormal function of
diacylglycerol (DAG)-dependent protein kinase C (PKC) isoforms
contributes to enhanced AP-1 activation (Rutberg et al, 1996). In
fact, the epidermis of AD patients is characterized by a marked
decrease in the content of ceramides that causes a dysfunction in the
cutaneous permeability barrier (Murata et al, 1996). Ceramides can
compete with the activating binding of DAGs on distinct PKC
isozymes, and interfere with PKC functions (Jones and Murray,
1995). A defect in ceramide generation could therefore result in
enhanced PKC activation, leading to an exaggerated AP-1
activation and, eventually, to hyperproduction of GM-CSF and
other proin¯ammatory cytokines by AD keratinocytes. In conclu-
sion, we provide initial evidence that enhanced cytokine produc-
tion by keratinocytes and skin hyperreactivity of AD patients may
be secondary to dysregulated activation of transcription factors of
the AP-1 family. Inasmuch as epithelial cells can play an important
role in the pathogenesis of atopic diseases, and are a useful target for
therapeutic intervention, studies on the mechanisms that regulate
expression of in¯ammatory genes in epithelial cells should
ultimately afford new molecular strategies for the control of atopic
diseases.
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